Companies included in LABU Page 2
This is LABU's own dated portfolio constitution. Share counts are the calculation basis for constituent revenue and earnings analytics; rounded weights are reference values only. This page shows positions 101–161 of 161.
| Ticker | Issuer | Shares owned | Unit | Reported weight |
|---|---|---|---|---|
| QURE | Uniqure N.V. | 97,163 | NS | 0.373567% |
| ANAB | AnaptysBio Inc. | 29,328 | NS | 0.371511% |
| CRVS | Corvus Pharmaceuticals Inc | 121,201 | NS | 0.354804% |
| MNKD | MANNKIND CORP | 625,921 | NS | 0.341374% |
| CDNA | Caredx Inc | 84,742 | NS | 0.339857% |
| KALV | KALVISTA PHARMACEUTICALS INC | 61,671 | NS | 0.316859% |
| IOVA | Iovance Biotherapeutics Inc | 466,051 | NS | 0.301785% |
| VIR | VIR Biotechnology Inc | 144,675 | NS | 0.284811% |
| GERN | GERON CORP | 951,040 | NS | 0.282257% |
| PGEN | Precigen Inc | 343,575 | NS | 0.275448% |
| SLS | SELLAS LIFE SCIENCES GROUP INC | 268,465 | NS | 0.256105% |
| TYRA | Tyra Biosciences Inc | 37,514 | NS | 0.251231% |
| ABSI | Absci Corp. | 259,355 | NS | 0.248664% |
| ANNX | Annexon Inc | 218,784 | NS | 0.247502% |
| KURA | Kura Oncology Inc. | 144,395 | NS | 0.245719% |
| SANA | Sana Biotechnology Inc | 380,569 | NS | 0.241298% |
| AVBP | ArriVent BioPharma Inc. | 40,097 | NS | 0.240247% |
| ORIC | ORIC Pharmaceuticals Inc. | 124,292 | NS | 0.23666% |
| RIGL | Rigel Pharmaceuticals Inc. | 40,551 | NS | 0.225852% |
| JANX | Janux Therapeutics Inc | 81,512 | NS | 0.225737% |
| CTMX | Cytomx Therapeutics Inc | 258,130 | NS | 0.209931% |
| SVRA | Savara Inc | 203,377 | NS | 0.20538% |
| SPRY | ARS Pharmaceuticals Inc | 126,616 | NS | 0.201555% |
| ZBIO | ZENAS BIOPHARMA INC | 51,847 | NS | 0.193044% |
| CGEM | Cullinan Therapeutics Inc | 74,789 | NS | 0.188093% |
| XNCR | Xencor Inc | 81,350 | NS | 0.187035% |
| IRWD | Ironwood Pharmaceuticals, Inc. | 233,156 | NS | 0.185351% |
| SION | Sionna Therapeutics Inc. | 23,827 | NS | 0.177707% |
| BCAX | Bicara Therapeutics Inc. | 40,903 | NS | 0.170111% |
| PURR | HYPERLIQUID STRATEGIES INC | 142,920 | NS | 0.165811% |
| PRME | Prime Medicine Inc | 232,034 | NS | 0.158523% |
| VOR | VOR BIOPHARMA INC | 54,358 | NS | 0.150119% |
| EBS | Emergent Biosolutions Inc | 91,705 | NS | 0.145451% |
| RGNX | Regenxbio Inc. | 79,519 | NS | 0.137464% |
| VNDA | VANDA PHARMACEUTICALS INC | 99,351 | NS | 0.135943% |
| N/A | N/A | 1 | NC | 0.133972% |
| TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | 29,328 | NS | 0.131524% |
| FDMT | 4D MOLECULAR THERAPEUTICS INC | 76,847 | NS | 0.131364% |
| ALLO | ALLOGENE THERAPEUTICS INC | 303,899 | NS | 0.124748% |
| ALT | Altimmune Inc. | 248,923 | NS | 0.124728% |
| VSTM | Verastem Inc | 117,456 | NS | 0.123593% |
| PRTA | Prothena Corporation PLC | 57,328 | NS | 0.122193% |
| LXEO | Lexeo Therapeutics Inc | 108,595 | NS | 0.119187% |
| MYGN | Myriad Genetics Inc. | 125,944 | NS | 0.115291% |
| ABUS | Arbutus Biopharma Corp. | 132,235 | NS | 0.107034% |
| RCKT | ROCKET PHARMACEUTICALS INC | 151,991 | NS | 0.101935% |
| OCGN | OCUGEN INC | 304,496 | NS | 0.10152% |
| AVXL | Anavex Life Sciences Corp. | 154,727 | NS | 0.099595% |
| AKBA | Akebia Therapeutics Inc. | 352,079 | NS | 0.093636% |
| IVVD | Invivyd Inc | 329,668 | NS | 0.088947% |
| MDXG | MiMedx Group Inc. | 133,086 | NS | 0.086178% |
| CATX | PERSPECTIVE THERAPEUTICS INC | 99,897 | NS | 0.075083% |
| CMPX | Compass Therapeutics Inc | 210,822 | NS | 0.071914% |
| REPL | Replimune Group Inc | 127,521 | NS | 0.06316% |
| DMRA | DAMORA THERAPEUTICS INC | 5,472 | NS | 0.02706% |
| INHIBRX INC CVR | INHIBRX INC CVR | 164,173 | NS | 0% |
| VERVE THERAPEUTICS INC (CVR) | VERVE THERAPEUTICS INC (CVR) | 82,531 | NS | 0% |
| 2200963D | OMNIAB INC | 14,783 | NS | 0% |
| 2200964D | OMNIAB INC | 14,783 | NS | 0% |
| NOVOB DC CVR | NOVOB DC CVR | 128,720 | NS | 0% |
| DREYFUS | DREYFUS | 0 | PA | 0% |
SEC N-PORT snapshot as of .